文献速递甲状腺疾病

超声引导下微波消融治疗低风险甲状腺微小乳头状癌:前瞻性研究的长期结果

US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: Longer-Term Results of a Prospective Study.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

这项前瞻性研究评估了超声引导下微波消融治疗低风险甲状腺微小乳头状癌的长期有效性。在119例无临床颈部或远处转移的单灶患者中,随访37.2±20.9个月,肿瘤体积从术后即刻的1.87±1.03 mL降至最终评估的0.01±0.04 mL(P<0.001),平均体积缩小率99.4±2.2%,93.9%病例(107例)获完全缓解。作者认为该技术可行且具有较好的长期有效性,似乎可作为非手术治疗选择补充现有推荐。

要点

  • 119例单灶低风险甲状腺微小乳头状癌患者接受超声引导下微波消融。
  • 随访37.2±20.9个月,肿瘤体积从1.87±1.03 mL降至0.01±0.04 mL(P<0.001)。
  • 平均体积缩小率99.4±2.2%,107例(93.9%)获完全缓解。

核心结论

  • 经皮微波消融在技术上可实现甲状腺微小乳头状癌的完全毁损,并显示出较好的长期有效性。
  • 作者认为,对于经过选择的低风险甲状腺微小乳头状癌患者,微波消融似乎是一种有效的非手术治疗方法,可补充当前推荐。

研究设计与样本

  • 前瞻性研究,经本机构伦理委员会批准。
  • 在超声引导下对119例无临床颈部或远处转移的单灶甲状腺微小乳头状癌患者行微波消融。
  • 以超声造影判断消融区超过肿瘤边缘,以避免边缘残留和复发。
  • 治疗后1、3、6、12个月随访超声和甲状腺功能,此后每6至12个月随访一次,并评估任何与微波消融相关的不良事件。

主要发现

  • 微波消融后随访时间为37.2±20.9个月(范围12-101个月)。
  • 肿瘤体积从微波消融后即刻的1.87±1.03 mL显著降至最终评估的0.01±0.04 mL(P<0.001),平均体积缩小率为99.4±2.2%。
  • 107例(93.9%)获得完全缓解。
  • 1例患者在26个月随访时发现颈部淋巴结转移,并成功接受了1次额外的微波消融治疗。
  • 未观察到远处转移。

临床怎么用

  • 对于经过选择的低风险甲状腺微小乳头状癌患者,作者认为微波消融似乎是一种有效的非手术治疗方法,可补充当前推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Papillary thyroid microcarcinoma (PTMC) has become a main cause of the extremely high incidence of thyroid carcinoma. This study aimed to evaluate the longer-term effectiveness of ultrasound (US)-guided microwave ablation (MWA) for treatment of low-risk PTMC with a large population. METHODS: This prospective study was approved by ethics committee of our institution. MWA was performed under US-guidance for 119 unifocal PTMC patients without clinically cervical or distant metastasis. The target ablation zone exceeded the tumor edge judged by contrast-enhanced US to avoid marginal residue and recurrence. US and thyroid function evaluation were followed at 1, 3, 6, and 12 months after treatment and every 6 to 12 months thereafter. Any adverse event associated with MWA was evaluated. RESULTS: The follow-up duration after MWA was 37.2 ± 20.9 months (range 12-101 months). Tumor volume decreased significantly from 1.87 ± 1.03 mL immediately after MWA to 0.01 ± 0.04 mL at the final evaluation (P < 0.001), with a mean volume reduction ratio of 99.4 ± 2.2% and 107 cases (93.9%) got complete remission. A patient was detected with cervical lymph node metastasis at 26-month follow-up and underwent 1 additional MWA treatment successfully. No distant metastasis was observed. All the acquired histological pathology results confirmed the absence of residual or recurrent tumor cells after MWA. No delayed complications associated with MWA were encountered for all patients. CONCLUSIONS: Percutaneous MWA is technically feasible for complete PTMC destruction and showed well longer-term effectiveness; thus, it seems to be an effective nonsurgical therapy to complement the current recommendation for selected low-risk PTMC patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yue WW, Qi L, Wang DD, et al. US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: Longer-Term Results of a Prospective Study. J Clin Endocrinol Metab. 2020. PMID: 32198508. doi:10.1210/clinem/dgaa128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。